Trishula Therapeutics, Inc.

ACTIVE

2268 Westborough Blvd Ste 302 # 263, 加利福尼亚州圣马特奥县, California, United Stateswww.trishulatx.comHolding1–10 employeesEstablished: 2020-01-01

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2020

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

60.0%

Phase 2

40.0%

Trial Status Distribution

Completed

60.0%

Recruiting

40.0%

Clinical Trials

Trials sponsored by this organization (5)

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Phase 2

Completed

interventional

Mar 2024194 participants

An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients not Previously Treated for Metastatic Pancreatic Adenocarcinoma

Phase 1

Recruiting

Feb 2024173 participants

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Phase 1

Completed

interventional

Mar 2020185 participants

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Phase 1

Completed

interventional

Apr 201956 participants

An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients not Previously Treated for Metastatic Pancreatic Adenocarcinoma

Phase 2

Recruiting

50 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations